Treace Medical sees 4Q sales rebound as foot/ankle portfolio expands. by Mike Evers on November 09, 2026 Treace Medical reported 3Q26 orthopedic sales of $48.3 million, down 4% compared to the third quarter of 2025. For the first nine months of the year, the company generated $140.8 million in orthopedic sales, down 6.2% compared to the prior period. Case volume grew at a double-digit rate, but a shift toward lower-priced minimally invasive products and fewer bunion kits sold weighed on revenue. Excluding sales to stocking distributors, bunion kit volume increased and revenue grew in mid-single digits. Management expects the impact of distributor orders on year-over-year comparisons to ease significantly after the third quarter. Treace's broader bunion portfolio continues to gain traction. Approximately 45% of Lapiplasty surgeons had used at least one of the company's three newer systems by the end of the quarter, up from 40% in the second quarter. Adoption is moving in both directions. About 30% of surgeons who first became Treace customers through Nanoplasty, Percuplasty or SpeedMTP have since used Lapiplasty. "Our strategy here is to build a large, diversified foot and ankle business off of our anchor as the leader in the bunion space," said Treace Medical founder and CEO John Treace. Beyond bunions, Treace fully launched its SuperBite compression screw system and is expanding its midfoot and hindfoot offering with HyperPlate XM, VitaFuse Bioactive Glass Graft and CartiBlaster joint preparation instruments. Management estimates that those four products, together with the Tailorplasty system for bunionettes, expand its U.S. addressable market by approximately $700 million. Treace expects to fully commercialize Tailorplasty and launch Lapiplasty Lightning in the first quarter of 2027. Treace narrowed its full-year revenue outlook to $206 million to $210 million from $204 million to $212 million, keeping the midpoint unchanged. The range represents a decline of 1% to 3% for 2026. Management expects sales to return to growth in the seasonally strongest fourth quarter as procedure volumes rise, new products contribute and the company begins comparing against quarters that already reflect the shift toward lower-priced systems. Orthopedic sales data. Unless otherwise noted, all orthopedic sales data is provided in USD millions. Orthoworld estimate orthopedic sales and growth rates on an as-reported basis. Orthopedic sales by Segment. | Segment | 3Q26 | 3Q25 | $ Chg | % Chg | | Trauma | $48.3 | $50.2 | ($2.0) | (3.9%) | | Segment | 9m26 | 9m25 | $ Chg | % Chg | | Trauma | $140.8 | $150.2 | ($9.3) | (6.2%) | Company Earnings. | / | Amt | % of Sales | | Sales | $48.3 | / | | Cost of Sales | $9.9 | 20.5% | | Sales and Marketing | $29.7 | 61.6% | | General and Admin | $15.7 | 32.5% | | R & D | $4.5 | 9.3% | | Other | $1.0 | 2.1% | | Net Earnings | ($12.6) | (26%) | Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.

Treace Medical Concepts (NASDAQ:TMCI) announces quarterly earnings results, beats expectations by $0.06 EPS. Treace Medical Concepts (NASDAQ:TMCI - Get Free Report) announced its quarterly earnings data on Friday. The company reported ($0.19) earnings per share for the quarter, beating the consensus estimate of ($0.25) by $0.06, FiscalAI reports. Treace Medical Concepts had a negative return on equity of 71.37% and a negative net margin of 28.99%. The firm had revenue of $48.25 million during the quarter, compared to analyst estimates of $47.80 million. Here are the key takeaways from Treace Medical Concepts' conference call: * Q3 revenue fell 4% year over year to $48.3 million, primarily due to lower-priced product mix and fewer bunion kits sold. Excluding stocking-distributor sales, revenue grew mid-single digits, while procedure volumes increased at a double-digit rate. * Treace narrowed its 2026 revenue outlook to $206 million-$210 million, still implying a 1%-3% annual decline, and expects to return to revenue growth in Q4. Management attributed the expected improvement to higher procedure volumes, easier comparisons on product mix, and contributions from new launches. * Profitability and cash trends improved: Q3 adjusted EBITDA was positive $0.3 million versus a $2.6 million loss a year earlier, operating expenses fell 10%, and year-to-date cash usage declined 53%. Full-year adjusted EBITDA is still expected to be a loss of $1 million-$2 million. * The company is expanding beyond its core bunion products with 2026 launches it estimates add about $700 million of U.S. addressable market; nearly 45% of Lapiplasty surgeons had adopted at least one of its newer bunion systems by Q3. Management sees broader product adoption as a growth opportunity, though it cautioned that newer products may keep average revenue per case below historical levels. Treace Medical Concepts stock performance. Shares of NASDAQ TMCI traded down $0.15 during midday trading on Friday, hitting $4.03. The company's stock had a trading volume of 596,717 shares, compared to its average volume of 616,914. The company has a debt-to-equity ratio of 0.83, a quick ratio of 1.95 and a current ratio of 2.90. Treace Medical Concepts has a 1-year low of $1.17 and a 1-year high of $5.25. The firm's fifty day moving average price is $4.40 and its 200-day moving average price is $3.28. The firm has a market cap of $262.09 million, a P/E ratio of -4.33 and a beta of 1.59. Insiders place their bets. In other Treace Medical Concepts news, CEO John Treace acquired 11,000 shares of the company's stock in a transaction that occurred on Monday, August 24th. The shares were purchased at an average price of $4.34 per share, for a total transaction of $47,740.00. Following the completion of the purchase, the chief executive officer directly owned 7,404,383 shares in the company, valued at $32,135,022.22. The trade was a 0.15% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. Insiders have bought a total of 55,944 shares of company stock worth $246,841 in the last quarter. 23.42% of the stock is owned by corporate insiders. Analysts set new price targets. Several brokerages have recently commented on TMCI. Truist Financial lifted their target price on Treace Medical Concepts from $4.00 to $5.00 and gave the stock a "hold" rating in a research report on Monday, August 10th. Weiss Ratings raised Treace Medical Concepts from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Monday, August 31st. One analyst has rated the stock with a Buy rating, four have issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Reduce" and an average price target of $5.17. About Treace Medical Concepts. Treace Medical Concepts, Inc is a medical device company focused on developing and commercializing products for the surgical treatment of bunion deformities and other conditions affecting the foot and ankle. The company's technologies are designed to address the underlying structural causes of bunions and support more stable correction than traditional surgical approaches. Treace's primary product is the Lapiplasty 3D Bunion Correction System, which is used by foot and ankle surgeons to correct bunions in three dimensions. Receive News & Ratings for Treace Medical Concepts Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Treace Medical Concepts and related companies with MarketBeat.com's FREE daily email newsletter.